Literature DB >> 10625171

NF1 gene and neurofibromatosis 1.

S A Rasmussen1, J M Friedman.   

Abstract

Neurofibromatosis 1 (NF1), also known as von Recklinghausen disease, is an autosomal dominant condition caused by mutations of the NF1 gene, which is located at chromosome 17q11.2. NF1 is believed to be completely penetrant, but substantial variability in expression of features occurs. Diagnosis of NF1 is based on established clinical criteria. The presentation of many of the clinical features is age dependent. The average life expectancy of patients with NF1 is probably reduced by 10-15 years, and malignancy is the most common cause of death. The prevalence of clinically diagnosed NF1 ranges from 1/2,000 to 1/5,000 in most population-based studies. A wide variety of NF1 mutations has been found in patients with NF1, but no frequently recurring mutation has been identified. Most studies have not found an obvious relation between particular NF1 mutations and the resulting clinical manifestations. The variability of the NF1 phenotype, even in individuals with the same NF1 gene mutation, suggests that other factors are involved in determining the clinical manifestations, but the nature of these factors has not yet been determined. Laboratory testing for NF1 mutations is difficult. A protein truncation test is commercially available, but its sensitivity, specificity, and predictive value have not been established. No general, population-based molecular studies of NF1 mutations have been performed. At this time, it appears that the benefits of population-based screening for clinical features of NF1 would not outweigh the costs of screening.

Entities:  

Mesh:

Year:  2000        PMID: 10625171     DOI: 10.1093/oxfordjournals.aje.a010118

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  122 in total

1.  Two pathogenic NF1 gene mutations identified in DNA from a child with mild phenotype.

Authors:  Yunus Kasim Terzi; Burcu Sirin; Guzen Hosgor; Esra Serdaroglu; Banu Anlar; Sabiha Aysun; Sukriye Ayter
Journal:  Childs Nerv Syst       Date:  2011-12-09       Impact factor: 1.475

2.  Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Authors:  Trent R Hummel; Walter J Jessen; Shyra J Miller; Lan Kluwe; Victor F Mautner; Margaret R Wallace; Conxi Lázaro; Grier P Page; Paul F Worley; Bruce J Aronow; Elizabeth K Schorry; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

3.  Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.

Authors:  Ye Won Jeon; Ra Mi Kim; Seung Taek Lim; Hyun Joo Choi; Young Jin Suh
Journal:  J Breast Cancer       Date:  2015-03-27       Impact factor: 3.588

4.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

5.  Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab.

Authors:  Brett J Theeler; Benjamin Ellezam; Shlomit Yust-Katz; John M Slopis; Monica E Loghin; John F de Groot
Journal:  J Neurol       Date:  2014-05-25       Impact factor: 4.849

Review 6.  Gastrointestinal stromal tumors.

Authors:  Maureen J O'Sullivan
Journal:  Pediatr Surg Int       Date:  2009-10       Impact factor: 1.827

7.  Cerebral vasculopathy in a Chinese family with neurofibromatosis type I mutation.

Authors:  Jian-Tao Liang; Li-Rong Huo; Yu-Hai Bao; Zhen-Yu Wang; Feng Ling
Journal:  Neurosci Bull       Date:  2013-11-11       Impact factor: 5.203

8.  Expression analysis of genes lying in the NF1 microdeletion interval points to four candidate modifiers for neurofibroma formation.

Authors:  B Bartelt-Kirbach; M Wuepping; M Dodrimont-Lattke; D Kaufmann
Journal:  Neurogenetics       Date:  2008-10-11       Impact factor: 2.660

Review 9.  Hereditary syndromes predisposing to endocrine tumors and their skin manifestations.

Authors:  Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

10.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

Authors:  Faris Farassati; Weihong Pan; Farnaz Yamoutpour; Susann Henke; Mark Piedra; Silke Frahm; Said Al-Tawil; Wells I Mangrum; Luis F Parada; Samuel D Rabkin; Robert L Martuza; Andreas Kurtz
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.